WebMar 4, 2024 · Scientists at London-based GlaxoSmithKline recently reported on a series of oral STING agonists tested in mice, and Bristol-Myers Squibb recently reported … WebNov 9, 2024 · GSK plans to begin clinical testing of the dimeric amidobenzimidazole STING agonist next year to treat solid tumors. The STING pathway is increasingly being …
Abstract 5554: Preclinical characterization of GSK532, a novel STING ...
WebMar 14, 2024 · Contact: US GSK Clinical Trials Call Center 877-379-3718 [email protected] : Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466 [email protected] : Principal Investigator: Lillian Siu : Japan: GSK Investigational Site: Recruiting: Chiba, Japan, 277-8577 : Contact: US GSK … WebDrug Detail. Drug Name. GSK3745417. Trade Name. Synonyms. GSK-3745417 GSK 3745417. Drug Descriptions. GSK3745417 is an agonist to stimulator of interferon genes (STING, TMEM173), which activates the immune system by stimulating cells in the tumor microenvironment ( PMID: 31355488 ). DrugClasses. imtv pc assembly
The Sting is dead; long live the Sting Evaluate
WebBackground Doublet combination therapies targeting immune checkpoints have shown promising efficacy in patients with advanced solid tumors, but it is unknown if rational triplet combinations will be well tolerated and associated with improved antitumor activity. The objective of this trial was to determine the recommended phase 2 doses (RP2Ds) and to … WebJun 8, 2024 · Blockade of the inhibitory receptor TIM-3 shows efficacy in cancer immunotherapy clinical trials. TIM-3 inhibits production of the chemokine CXCL9 by XCR1+classical dendritic cells (cDC1), thereby limiting antitumor immunity in … WebQ4 2024 Pipeline List ( XLSX - 25.7KB ) At GSK, our pipeline is focused on unlocking the science of the immune system, human genetics and advanced technologies to develop … imtt therapeuten